

# Fortis Healthcare Limited

Earnings Presentation – Q4 & FY2019



*“Saving and Enriching Lives”*



May 24, 2019

# Disclaimer

This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company.

Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities of the company for sale in the United States, India or any other jurisdiction.

Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering in the United States may be made only by means of an offering document that may be obtained from the Company and that will contain detailed information about the Company and its management, as well as financial statements. Any offer or sale of securities in a given jurisdiction is subject to the applicable laws of that jurisdiction.

This presentation contains forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements.


The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this presentation, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes.

By attending or assessing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date.

# Agenda

1. Key Highlights and Immediate Priorities
2. Key Financial Summary – Q4FY19 and FY2019
3. Executive Results Summary
4. Performance Review – Hospitals Business
5. Performance Review – Diagnostics Business
6. Appendix



*Well Positioned to become a premier tertiary care healthcare delivery organization*

**BUSINESS RECOVERY ON TRACK**

**RENEWED FOCUS ON WORLD-CLASS HEALTHCARE DELIVERY & EXCEPTIONAL PATIENT CARE**

**RHT PORTFOLIO OF ASSETS ACQUISITION COMPLETE**

# 1. Key Highlights and Immediate Priorities

# Key Highlights and Immediate Priorities

## Completed

- IHH's infusion of INR 4,000 Cr
- RHT portfolio acquisition primarily through equity
- Savings of Clinical Establishment (CE) Fees by approx. INR 270 Crs leading to improved profitability

- Strengthened credit rating to BBB- (Investment Grade) by ICRA and CARE
- Lowered borrowing cost at 10-11% currently vs 15%+ for previous borrowings

- Reconstituted Board with 5 IHH nominees, 3 IDs and MD & CEO
- Strengthening and Institutionalizing processes and systems
- New MD & CEO and CFO appointed

Strengthen  
Balance Sheet

Improve  
Liquidity

Streamline  
Org Structure  
& Improve  
Efficiency

## WIP

- Proposed divestment of non-core assets :
  - 28.89% Stake in MSCL (SPA signed on May 17, 2019)
  - RHT\* / Stellant Capital\*\*
  - Select other non-core assets

- Better working capital management
- Ongoing dialogue with Banks for refinancing existing debt to further reduce costs
- Non- core asset divestment as above

- Simplified organisation structure
- Manpower productivity and cost optimisation
- Synergies via procurement, Supply Chain, IT infrastructure and Services

\*Fortis owns 25.14% stake in RHT Health Trust (RHT) which is primarily a shell trust with residual cash post the asset divestment to Fortis;

\*\*Stellant Capital Advisory Services Pvt Ltd is 100% indirectly owned by Fortis which further owns 100% of RHT Health Trust Managers Pte Ltd (RHTTM), Trustee Manager to RHT Health Trust. Post the RHT transaction, both the assets have no strategic relevance to the company.

## 2. Key Financial Summary – Q4FY19 and FY2019

# Q4 FY2019 – Financial Highlights

## Operations report positive Profit before Tax\*

- Consolidated Revenues at INR 1,184 Cr, up 9.0%
  - Hospital Business Revenues at INR 919 Cr, up 5.8%
  - Diagnostics Business Net Revenues at INR 217 Cr, up 2.3%
- Operating margins (EBITDAC) at 15.4% versus 12.7% in Q4 FY 18
  - Hospital Business EBITDAC margins at 11.7% versus 12.1% in Q4 FY 18
  - Diagnostics Business EBITDA margins at 22.6% versus 15.6% margin in Q4 FY 18
- Operating EBITDA margins improved to 14.1% from 6.9% in Q4FY18. Adjusted for one off EBITDA from RHTTM, margins for the quarter were at 12.4%.
- Interest cost reduction by 42% from Q3FY19 to INR 64.8 Cr in Q4 FY19. Excluding one-off costs of Q3FY19, interest cost reduced by approx. INR 13 Cr in Q4FY19


*\*PBT is prior to other income, any exceptional items and the one-off EBITDA of RHTTM as a result of the completion of the RHT transaction*



# Q4 FY2019 – Financial Highlights (Cont..)

- Clinical establishment fees reduced from INR 63 Cr in corr. previous quarter to INR 15 Cr in Q4 FY 19 (CE fees only from 1st Jan – 14th Jan). No CE fees from Q1FY 20.
- PATMI at INR 135.6 Cr versus loss of INR 932 Cr in Q4 FY18
- Exceptional expenses in Q4FY19 are primarily due to costs associated with extension of RHT transaction; for Q4FY18 one offs include impairment of investments / assets and certain provisions taken.
- Q4FY19 also witnessed significant share in associate of approx. INR 333 Cr mainly due to RHT's profit related to divestment of assets to Fortis in January 2019.

# FY 2019 – Quarterly Revenues and Margins



- Consistent improvement in Operating Performance
- Excluding the financials of RHTTM, consolidated margins on a like to like basis have expanded from 7.7% in Q1 to 13.7% in Q4.

# FY2019 – Financial Highlights

Business performance witnessed traction beginning Q2FY 19 and continued to show an encouraging uptrend in Q3 and Q4FY19

- Consolidated Revenues at INR 4,469 Cr, a decline of 2% versus FY18. Largely due to the challenging environment witnessed in H1FY19.
  - Hospital Business Revenues at INR 3,527 Cr, lower by 4.2%
  - Diagnostic Business Net Revenues at INR 877 Cr, up by 2.7% .
- Consolidated Operating margins (EBITDAC) at 12.1% versus 14.4 % in FY 18
  - Hospital EBITDAC margins at 9.5% versus 13.6% in FY 18.
  - Diagnostics EBITDA margin at 20.6% versus a margin 18.9% in previous year.
- Consolidated Operating EBITDA stood at INR 326 Cr; margin of 7.3% versus 8.5% in previous year
- PATMI\* at loss of INR 299 Cr versus loss of INR 1,009 Cr in FY 18

\* FY 19 and FY18 had exceptional losses due to impairment of investments / goodwill/ assets and one off expenses; for FY 18 exceptional losses also includes one offs for certain provisions taken – total of INR 907 Cr

\*FY19 includes significant share in associate mainly due to RHT's profit related to divestment of assets to Fortis in January 2019.

## 3. Executive Results Summary

# Executive Summary – Q4FY19

## Consolidated Financials

| Particulars (INR Cr)            | Q4FY18         | Q3FY19         | Q4FY19       | QoQ<br>% Change | QotQ<br>% Change |
|---------------------------------|----------------|----------------|--------------|-----------------|------------------|
| <b>Revenue</b>                  | 1,086.4        | 1,103.3        | 1,184.1      | 9.0%            | 7.3%             |
| <b>Operating EBITDAC*</b>       | <b>138.3</b>   | <b>136.6</b>   | <b>182.2</b> | 31.7%           | 33.3%            |
| <b>Operating EBITDAC margin</b> | <b>12.7%</b>   | <b>12.5%</b>   | <b>15.4%</b> |                 |                  |
| Operating EBITDA                | 75.1           | 68.3           | 167.1        | 122.5%          | 144.7%           |
| Operating EBITDA margin         | 6.9%           | 6.2%           | 14.1%        |                 |                  |
| PBT pre-exceptional / FX        | (72.2)         | (57.5)         | 52.7         |                 |                  |
| <b>PATMI ^</b>                  | <b>(932.0)</b> | <b>(197.0)</b> | <b>135.6</b> |                 |                  |

- Operating EBITDA increased significantly due to acquisition of RHT India assets , one off income at RHTTM level and the operational margin expansion witnessed in the diagnostics business
- PATMI for Q3FY19 primarily impacted by exceptional losses/one off expenses pertaining to impairments related to the goodwill and of certain assets, one off financial and legal expenses and higher finance cost.
- PATMI for Q4 FY 18 impacted by impairment of Investments / goodwill and one off expenses related to certain provisions.
- PATMI for Q4FY19 includes one time significant share in associate of approx. INR 333 Cr mainly due to RHT's profit as a result of the divestment of assets to Fortis in January 2019.

# Executive Summary – FY19

## Consolidated Financials

| Particulars (INR Cr)     | FY18             | FY19           | % Change |
|--------------------------|------------------|----------------|----------|
| Revenue                  | 4,560.8          | 4,469.4        | -2.0%    |
| Operating EBITDAC*       | 654.7            | 541.3          | -17.3%   |
| Operating EBITDAC margin | 14.4%            | 12.1%          |          |
| Operating EBITDA         | 389.1            | 325.6          | -16.3%   |
| Operating EBITDA margin  | 8.5%             | 7.3%           |          |
| PBT pre-exceptional / FX | (23.0)           | (163.8)        |          |
| <b>PATMI ^</b>           | <b>(1,009.2)</b> | <b>(298.9)</b> |          |

- ^PATMI for FY19 primarily impacted in H2FY 19 as a result of exceptional losses/one off expenses pertaining to impairments related to the goodwill and of certain assets, one off financial and legal expenses and higher finance cost due to one off costs related to pre closure/other charges for high cost debts. During Q4FY19, the company witnessed one time significant share in associate of approx. INR 333 Cr mainly due to RHT's profit related to divestment of assets to Fortis in January 2019.
- PATMI for FY 18 impacted by impairment of Investments / goodwill and one off expenses related to provisions made largely in Q4 FY 18

\*EBITDAC refers to EBITDA before net business trust costs


## Balance Sheet – March 31, 2019

| Balance Sheet (INR Cr)           | March 31, 2018 | Dec 31, 2018  | March 31, 2019 |
|----------------------------------|----------------|---------------|----------------|
| Shareholder's Equity             | 5,317          | 8,932         | 7,175          |
| Debt                             | 1,959          | 1,567         | 2,009          |
| <b>Total Capital Employed</b>    | <b>7,276</b>   | <b>10,498</b> | <b>9,184</b>   |
| Net Fixed Assets (includes CWIP) | 3,169          | 3,010         | 5,206          |
| Goodwill                         | 2,049          | 1,920         | 3,716          |
| Investments                      | 1,397          | 1,225         | 190            |
| Cash and Cash Equivalents        | 555            | 3,926         | 986            |
| Net Current Assets               | 106            | 418           | (918)          |
| <b>Total Assets</b>              | <b>7,276</b>   | <b>10,498</b> | <b>9,184</b>   |
| Net Debt / (cash)                | 1,404          | (2,359)       | 1,023          |
| Net Debt to Equity               | 0.26x          | -             | 0.14x          |

# Business Summary Highlights


INR Crore

## Hospital Business



INR Crore

## Diagnostic Business



- Overall Business continuing to witness traction in operations on YoY basis
- Hospital business performance witnessed steady improvement despite challenging conditions
  - EBITDAC margin improved from 5.1% in Q1 to 11.7% in Q4 FY 19
  - Witnessed uptick in revenue growth in Q4 FY 19 versus trailing and corr. quarter
    - Occupancy at 62% in Q1 to vs 67.8% in Q4 FY 19
- Diagnostic business margins significantly improved from 18.7% in Q1 to 22.6% in Q4 FY 19.



## 4. Performance Review – Hospital Business

# India Hospital Business – Q4 FY2019

| Particulars                     | Q4FY18       | Q3FY19       | Q4FY19       | QoQ<br>% Change |
|---------------------------------|--------------|--------------|--------------|-----------------|
|                                 | (INR Cr.)    | (INR Cr.)    | (INR Cr.)    |                 |
| Operating Revenue               | 868.5        | 889.0        | 918.5        | 5.8%            |
| <b>Operating EBITDAC*</b>       | <b>105.2</b> | <b>99.6</b>  | <b>107.2</b> | <b>1.9%</b>     |
| <b>Operating EBITDAC margin</b> | <b>12.1%</b> | <b>11.2%</b> | <b>11.7%</b> |                 |
| Net BT Costs                    | 63.3         | 68.3         | 15.1         | -76.1%          |
| <b>Operating EBITDA</b>         | <b>41.9</b>  | <b>31.3</b>  | <b>92.1</b>  | <b>119.7%</b>   |
| Other Income                    | 1.3          | 40.7         | 11.6         |                 |
| <b>EBITDA</b>                   | <b>43.3</b>  | <b>72.0</b>  | <b>103.7</b> | <b>139.7%</b>   |

- International patient revenue at INR 100 Cr, + 2% growth over corr. quarter
- Key Hospitals revenue growth (over Q4 FY18)
  - Jaipur +13%
  - Mulund + 13%
  - Anandapur +26%
  - Vashi +9%
  - Ludhiana +18%
- Key hospitals that witnessed operating profitability growth over Q4FY18 are Noida, Anandpur, Mohali, Ludhiana and CH Road

\*EBITDAC refers to EBITDA before net business trust (BT) costs


# India Hospital Business – FY2019

| Particulars                     | FY18         | FY19         | % Change      |
|---------------------------------|--------------|--------------|---------------|
|                                 | (INR Cr)     | (INR Cr)     |               |
| Operating Revenue               | 3,683.0      | 3,526.9      | -4.2%         |
| <b>Operating EBITDAC*</b>       | <b>500.5</b> | <b>336.3</b> | <b>-32.8%</b> |
| <b>Operating EBITDAC margin</b> | <b>13.6%</b> | <b>9.5%</b>  |               |
| Net BT Costs                    | 265.6        | 215.8        | -18.8%        |
| <b>Operating EBITDA</b>         | <b>234.9</b> | <b>120.5</b> | <b>-48.7%</b> |
| Other Income                    | 101.9        | 74.9         |               |
| <b>EBITDA</b>                   | <b>336.8</b> | <b>195.4</b> | <b>-42.0%</b> |


\*EBITDAC refers to EBITDA before net business trust (BT) costs

# Key Performance Metrics – Hospital Business


Occupancy (%)



ARPOB (INR Cr)



ALOS (Days)



70%



FY18

67%



FY19

1.49



FY18

1.51



FY19

3.48




FY18

3.39




FY19

# Key Hospitals Performance




# Key Hospitals - KPIs


## Occupancy



## ARPOB (INR Cr)



# Specialty Mix – FY2019



86 Heart Transplants

Over 7,200 Knee Implants

Over 580 Hip Implants

412 Renal Transplants

210 Liver Transplants

114 Bone Marrow Transplants

# Select Hospital Business Highlights – FY2019

## CLINICAL EXCELLENCE

- Strengthened clinical teams in the NCR region in the number of specialties including amongst others Oncology, Neurology and Orthopaedics
- East India's first heart transplant undertaken at Fortis Anandpur, Kolkata
- Heart Transplant commenced at BG Road Bengaluru. Heart Transplant procedure across 5 Fortis facilities including Malar, FEHI, Anandpur, BG Road and Mulund

## BUSINESS INITIATIVES & COST EFFICIENCIES

- Robust growth being witnessed from digital and marketing business channels across many facilities
- International Sales stood at INR 397 Cr (~11.3% to revenues vs 11% in FY18); New international sales structure rolled out for focused business development and revenue generation
- Focus on strengthening working capital management .i.e. receivables and inventories
- Project underway to enhance manpower productivity
- Fortis and IHH working to bring in synergistic benefits and best practices across the network to drive revenues and optimize costs .i.e. procurement / supply chain / IT



# Key Initiatives – FY2019

- Fortis Hospital, Shalimar Bagh, launched the Cancer Care Institute. Equipped with the latest technology in cancer care along with experienced specialists, the facility offers a trans- disciplinary and multi – modality approach in oncology. The facility also offers bone marrow transplant treatment, nuclear medicine and Interventional Radiology services.
- Fortis Hospital, Bannerghatta Road, Bengaluru, acquired the Da Vinci Xi system, the most advanced Robotic Surgery technology in the world.
- Fortis Memorial Research Institute launched a specialised Anemia Clinic at its facility in Gurugram. aimed at creating awareness and combating blood disorders at an early stage
- To mark World Arthritis Day and World Osteoporosis Day, Hiranandani Hospital, Vashi- A Fortis Network Hospital, launched an exclusive healthcare programme for the elderly - 'Seniors First'.
- Fortis Escorts Heart Institute (FEHI) launched a Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI) programme. The Institute is the only facility in the Fortis network to offer the specialized programme.
- A specialised shoulder clinic was launched at Fortis Hospital, CG Road, Bengaluru positioning it well to become an advanced treatment centre for sports injuries.

# Successes in Clinical Excellence – FY2019

First in India: Doctors at Fortis Escorts, Okhla Road, use artificial lung support (ECMO) to treat pregnant Swine Flu patient; saved both mother and unborn child

A team of doctors at Fortis Noida successfully saved a 36 years road accident victim who was badly injured that his lungs had protruded out of his chest. The Doctors reconstructed his chest wall and repaired lungs thus giving him new lease of life

Fortis Escorts Heart Institute achieved yet another milestone by performing the India's first "Protected Angioplasty and Stenting Procedure" with the support of an Impella Heart Pump on an 86-year-old patient suffering from life threatening heavily calcified triple vessel and left main artery blockages.

An 8-year old boy from Iraq suffering from a rare bone cancer, Ewing's Sarcoma, was successfully treated at Fortis Hospital, Mulund. The doctors treated adopted Radical Resection, Extracorporeal Radiation Therapy and re-implantation to treat thus saving the child from undergoing an amputation

A team of doctors at Fortis Hospital, Bannerghatta Road, Bengaluru conducted its maiden complex paediatric heart transplant to save a 13-year-old boy from Karnataka who was suffering from dilated cardiomyopathy.

In a rare and unique feat, a patient suffering from hemophilia, a genetic disorder impairing the body's ability to clot blood, a process needed to stop bleeding, successfully underwent knee replacement surgery at Fortis hospital, BG Road, Bengaluru.

# Key Awards and Recognitions - FY2019

Fortis Healthcare has won the prestigious FICCI Healthcare Excellence Awards 2018 in the Social Initiative category for the 'Umeed-Dhadkan' programme.

Four Fortis hospitals won laurels at the Advantage Healthcare India - Medical Value Travel Awards 2018. (1) Fortis Escorts Heart Institute won the award in the Interventional Cardiology category. (2) Fortis Malar Hospital won the award in Heart Transplant category. (3) Fortis Vasant Kunj was recognized in the Kidney Transplants category. (4) FMRI won the award in the Cosmetic Surgery category.

Fortis BG Road, becomes first hospital in Bengaluru to win the coveted 'Pharmacie de Qualite' Certification. Considered the highest standard in pharmacy certification, the coveted Pharmacy De Qualite' certification programme has been brought to India by Abbott in association with Bureau Veritas S.A – a global testing, inspection and certification services provider in order to create 'Pharmacies as centre of excellence'.


Fortis Hospital, Mohali, has been honoured with the 'Green Hospital' award at the AHPI Healthcare Excellence Awards 2019, instituted by the Association of Healthcare Providers (India).

SL Raheja Hospital, Mahim - A Fortis Associate, won the 'Green Hospital' award for its environment conservation initiatives. The award was presented in recognition of the various environment friendly initiatives at the hospital for energy efficiency and water conservation.

## 5. Performance Review – Diagnostics Business

# Diagnostic Business – Q4FY19

- Net Operating revenue at INR 217 Cr, +2.3% (*like for like growth ~6%*)
- Operating EBITDA margin stood at 22.6% compared to 15.6% in Q4FY18 & 17.6% in Q3FY19
- SRL conducted over 7.40 million tests during Q4FY19 compared to 7.37 mn tests conducted in Q4FY18 (excluding joint ventures)
- Business has achieved significant improvement in margins both on a quarter and YoY basis.
  - Savings in direct cost as a result of improved lab efficiency and vendor costs negotiations
  - Savings in manpower costs as a result of staffing optimization and cost control in operating expenses




# Diagnostic Business – FY2019

- Net Operating revenue at INR 877 Cr, +2.7% (*like for like growth ~3%*)
- Operating EBITDA margin stood at 20.6% compared to 18.9% in FY18


## FUTURE GROWTH DRIVERS

- Focus on expansion of franchisee and owned collection center network and driving revenue through initiatives to increase revenue contribution from the existing network
- Enhanced product offerings in preventive packages portfolio and focus on key lifestyle diseases
- Introduction of new tests and technologies driven by central R&D efforts
- Digital initiatives such as mobile app and CRM have started yielding results




# Key Performance Metrics

Number of Tests and Average Realizations\*



Direct Cost per test (INR)




\*excluding joint ventures


# Revenue Mix

## Geographic Mix

FY2019




FY2018




## Customer Mix

FY2019



FY2018





## 6. Appendix

# India Consolidated P&L – Q4 FY2019

| Particulars   | Q4FY18         | Q3FY19         | Q4FY19         | QoQ % Change |
|---|----------------|----------------|----------------|--------------|
|   | (INR Cr)       | (INR Cr)       | (INR Cr)       |              |
| <b>Operating Revenue</b>                                    | 1,080.4        | 1,098.2        | 1,135.3        | 5.1%         |
| <b>Operating EBITDAC*</b>                                   | <b>138.2</b>   | <b>136.3</b>   | <b>156.2</b>   | <b>13.0%</b> |
| <b>Operating EBITDAC margin</b>                             | <b>12.8%</b>   | <b>12.4%</b>   | <b>13.8%</b>   |              |
| Net BT Costs  | 63.3           | 68.3           | 15.1           | -76.1%       |
| <b>Operating EBITDA</b>                                     | <b>75.0</b>    | <b>68.0</b>    | <b>141.1</b>   | <b>88.2%</b> |
| Other Income  | 1.0            | 44.4           | 10.4           |              |
| <b>EBITDA</b>   | <b>75.9</b>    | <b>112.4</b>   | <b>151.6</b>   | <b>99.6%</b> |
| Finance Costs ^^  | 63.9           | 110.6          | 64.7           |              |
| Depreciation & Amortization                                 | 60.2           | 60.1           | 59.9           |              |
| <b>PBT before Forex</b>                                     | <b>(48.2)</b>  | <b>(58.3)</b>  | <b>27.0</b>    |              |
| Foreign Exchange (Loss)/ Gain                               | (2.9)          | (1.4)          | (7.3)          |              |
| <b>PBT before Exceptional Item</b>                          | <b>(51.1)</b>  | <b>(59.7)</b>  | <b>19.7</b>    |              |
| Exceptional (Loss)/ Gain^                                   | (805.7)        | (157.9)        | (45.5)         |              |
| Tax Expense   | (4.5)          | (21.1)         | 177.7          |              |
| <b>PAT before minority interest and share in associates</b> | <b>(852.3)</b> | <b>(196.6)</b> | <b>(203.5)</b> |              |
| Share in Associates**                                       | 3.2            | 14.1           | 329.9          |              |
| <b>PAT after minority interest and share in associates</b>  | <b>(866.8)</b> | <b>(199.5)</b> | <b>110.9</b>   |              |

\*EBITDAC refers to EBITDA before net business trust costs

^Exceptional items primarily pertain to impairments related to the goodwill and of certain assets. These in addition, also include certain one off financial and legal expenses related to advisory fees for corporate transactions completed. ^^ Higher finance cost in Q3FY19 due to one off costs related to pre closure/other charges for high cost debts. \*\*Higher Share in Associate in Q4FY19 is mainly due to RHT's profit on divestment of assets to Fortis in January 2019.

# India Consolidated P&L – FY2019

| Particulars  | FY18           | FY19           | % Change      |
|--|----------------|----------------|---------------|
|  | (INR Cr.)      | (INR Cr.)      |               |
| Operating Revenue                                    | 4,536.9        | 4,404.1        | -2.9%         |
| Operating EBITDAC*                                   | <b>661.7</b>   | <b>516.5</b>   | <b>-21.9%</b> |
| Operating EBITDAC margin                             | <b>14.6%</b>   | <b>11.7%</b>   |               |
| Net BT Costs   | 265.6          | 215.8          | -18.8%        |
| Operating EBITDA                                     | <b>396.2</b>   | <b>300.8</b>   | <b>-24.1%</b> |
| Other Income   | 106.3          | 79.4           |               |
| EBITDA   | <b>502.5</b>   | <b>380.2</b>   | <b>-24.3%</b> |
| Finance Costs  | 256.5          | 335.7          |               |
| Depreciation & Amortization                          | 237.4          | 232.6          |               |
| PBT before Forex                                     | <b>8.6</b>     | <b>(188.1)</b> |               |
| Foreign Exchange (Loss)/ Gain                        | (22.2)         | (2.2)          |               |
| PBT before Exceptional Item                          | <b>(13.5)</b>  | <b>(190.3)</b> |               |
| Exceptional (Loss)/ Gain^                            | (858.1)        | (316.4)        |               |
| Tax Expense  | 24.8           | 107.7          |               |
| PAT before minority interest and share in associates | <b>(896.4)</b> | <b>(614.4)</b> |               |
| Share in Associates**                                | 46.0           | 353.1          |               |
| PAT after minority interest and share in associates  | <b>(925.2)</b> | <b>(336.6)</b> |               |

\*EBITDAC refers to EBITDA before net business trust costs

^Exceptional items primarily pertain to impairments related to the goodwill and of certain assets. These in addition, also include certain one off financial and legal expenses related to advisory fees for corporate transactions completed

\*\*Higher Share in Associate in FY19 is mainly due to RHT's profit on divestment of assets to Fortis in January 2019.



# Group Consolidated P&L – Q4 FY2019

| Particulars   | Q4FY18         | Q3FY19         | Q4FY19         | QoQ % Change  |
|---|----------------|----------------|----------------|---------------|
|   | (INR Cr.)      | (INR Cr.)      | (INR Cr.)      |               |
| <b>Operating Revenue</b>                                    | 1,086.4        | 1,103.3        | 1,184.1        | 9.0%          |
| <b>Operating EBITDAC*</b>                                   | <b>138.3</b>   | <b>136.6</b>   | <b>182.2</b>   | <b>31.7%</b>  |
| <b>Operating EBITDAC margin</b>                             | <b>12.7%</b>   | <b>12.4%</b>   | <b>15.4%</b>   |               |
| Net BT Costs  | 63.3           | 68.3           | 15.1           | -76.1%        |
| <b>Operating EBITDA</b>                                     | <b>75.1</b>    | <b>68.3</b>    | <b>167.1</b>   | <b>122.5%</b> |
| Other Income  | (22.8)         | 45.3           | 10.5           |               |
| <b>EBITDA</b>   | <b>52.2</b>    | <b>113.6</b>   | <b>177.5</b>   | <b>239.8%</b> |
| Finance Costs ^^  | 64.1           | 111.0          | 64.8           | 1.1%          |
| Depreciation & Amortization                                 | 60.3           | 60.1           | 60.0           |               |
| <b>PBT before Forex</b>                                     | <b>(72.2)</b>  | <b>(57.5)</b>  | <b>52.7</b>    |               |
| Foreign Exchange (Loss)/ Gain                               | 0.4            | (2.1)          | (6.8)          |               |
| <b>PBT before Exceptional Item</b>                          | <b>(71.8)</b>  | <b>(59.6)</b>  | <b>45.9</b>    |               |
| Exceptional (Loss)/ Gain ^                                  | (854.7)        | (157.9)        | (45.5)         |               |
| Tax Expense   | (9.2)          | (20.4)         | 182.6          |               |
| <b>PAT before minority interest and share in associates</b> | <b>(917.4)</b> | <b>(197.1)</b> | <b>(182.1)</b> |               |
| Share in Associates **                                      | 3.1            | 17.0           | 333.3          |               |
| <b>PAT after minority interest and share in associates</b>  | <b>(932.0)</b> | <b>(197.0)</b> | <b>135.6</b>   |               |

\*EBITDAC refers to EBITDA before net business trust costs

^Exceptional items primarily pertain to impairments related to the goodwill and of certain assets. These in addition, also include certain one off financial and legal expenses related to advisory fees for corporate transactions completed. ^^Higher finance cost in Q3FY19 due to one off costs related to pre closure/other charges for high cost debts. \*\*Higher Share in Associate in Q4FY19 is mainly due to RHT's profit on divestment of assets to Fortis in January 2019.

# Group Consolidated P&L – FY2019

| Particulars   | FY18             | FY19           | % Change      |
|---|------------------|----------------|---------------|
|   | (INR Cr.)        | (INR Cr.)      |               |
| Operating Revenue   | 4,560.8          | 4,469.4        | -2.0%         |
| Operating EBITDAC*  | <b>654.7</b>     | <b>541.3</b>   | <b>-17.3%</b> |
| Operating EBITDAC margin                                    | <b>14.4%</b>     | <b>12.1%</b>   |               |
| Net BT Costs  | 265.6            | 215.8          | -18.8%        |
| Operating EBITDA  | <b>389.1</b>     | <b>325.6</b>   | <b>-16.3%</b> |
| Other Income  | 84.7             | 80.4           |               |
| <b>EBITDA</b>   | <b>473.8</b>     | <b>406.0</b>   | <b>-14.3%</b> |
| Finance Costs   | 257.8            | 336.8          |               |
| Depreciation & Amortization                                 | 239.0            | 232.9          |               |
| <b>PBT before Forex</b>                                     | <b>(23.0)</b>    | <b>(163.8)</b> |               |
| Foreign Exchange (Loss)/ Gain                               | (34.8)           | 5.7            |               |
| <b>PBT before Exceptional Item</b>                          | <b>(57.8)</b>    | <b>(158.1)</b> |               |
| Exceptional (Loss)/ Gain ^                                  | (907.2)          | (316.4)        |               |
| Tax Expense   | 22.6             | 113.6          |               |
| <b>PAT before minority interest and share in associates</b> | <b>(987.6)</b>   | <b>(588.1)</b> |               |
| Share in Associates **                                      | 53.2             | 364.4          |               |
| <b>PAT after minority interest and share in associates</b>  | <b>(1,009.2)</b> | <b>(298.9)</b> |               |

\*EBITDAC refers to EBITDA before net business trust costs

^Exceptional items primarily pertain to impairments related to the goodwill and of certain assets. These in addition, also include certain one off financial and legal expenses related to advisory fees for corporate transactions completed.

\*\*Higher Share in Associate in Q4FY19 is mainly due to RHT's profit on divestment of assets to Fortis in January 2019.

**For further details please contact:**

**Anurag Kalra / Gaurav Chugh**

Investor Relations

+91-9810109253 / 9958588900

Fortis Healthcare Limited

**Thank You**